Summary: This phase 2 study evaluated the efficacy and safety of transitioning to zoledronate following romosozumab treatment in postmenopausal women with low bone mass. A single dose of 5 mg zoledronate generally maintained the robust BMD gains accrued with romosozumab treatment and was well tolerated. Introduction: Follow-on therapy with an antiresorptive agent is necessary to maintain the skeletal benefits of romosozumab therapy. We evaluated the use of zoledronate following romosozumab treatment. Methods: This phase 2, dose-finding study enrolled postmenopausal women with low bone mineral density (BMD). Subjects who received various romosozumab doses or placebo from months 0–24 were rerandomized to denosumab (60 mg SC Q6M) or placebo ...
[[abstract]]Objective: The discontinuation of denosumab for the treatment ofosteoporosis can result ...
Introduction: Romosozumab is a monoclonal antibody that binds to sclerostin (an inhibitor of the Win...
Background: Previous bisphosphonate treatment attenuates the bone-forming effect of teriparatide. W...
Summary This phase 2 study evaluated the efficacy and safety of transitioning to zoledronate followi...
Romosozumab is a therapy that stimulates bone formation and reduces bone resorption. In this study o...
Over 12 months, romosozumab increased bone formation and decreased bone resorption, resulting in inc...
Introduction: In women with postmenopausal osteoporosis denosumab discontinuation is associated with...
SUMMARY: In a 5-year study involving 119 postmenopausal women, zoledronic acid 4 mg given once-yearl...
Romosozumab, a humanized monoclonal antibody that binds and inhibits sclerostin, has the dual effect...
Context: Zoledronate is used to prevent bone loss following denosumab discontinuation but its effica...
In a 5-year study involving 119 postmenopausal women, zoledronic acid 4 mg given once-yearly for 2, ...
Romosozumab, a monoclonal anti-sclerostin antibody that has the dual effect of increasing bone forma...
Over 12 months, romosozumab increased bone formation and decreased bone resorption, resulting in inc...
Background: Sclerostin is an osteocyte-derived inhibitor of osteoblast activity. The monoclonal anti...
BACKGROUND: A single infusion of intravenous zoledronic acid decreases bone turnover and improves bo...
[[abstract]]Objective: The discontinuation of denosumab for the treatment ofosteoporosis can result ...
Introduction: Romosozumab is a monoclonal antibody that binds to sclerostin (an inhibitor of the Win...
Background: Previous bisphosphonate treatment attenuates the bone-forming effect of teriparatide. W...
Summary This phase 2 study evaluated the efficacy and safety of transitioning to zoledronate followi...
Romosozumab is a therapy that stimulates bone formation and reduces bone resorption. In this study o...
Over 12 months, romosozumab increased bone formation and decreased bone resorption, resulting in inc...
Introduction: In women with postmenopausal osteoporosis denosumab discontinuation is associated with...
SUMMARY: In a 5-year study involving 119 postmenopausal women, zoledronic acid 4 mg given once-yearl...
Romosozumab, a humanized monoclonal antibody that binds and inhibits sclerostin, has the dual effect...
Context: Zoledronate is used to prevent bone loss following denosumab discontinuation but its effica...
In a 5-year study involving 119 postmenopausal women, zoledronic acid 4 mg given once-yearly for 2, ...
Romosozumab, a monoclonal anti-sclerostin antibody that has the dual effect of increasing bone forma...
Over 12 months, romosozumab increased bone formation and decreased bone resorption, resulting in inc...
Background: Sclerostin is an osteocyte-derived inhibitor of osteoblast activity. The monoclonal anti...
BACKGROUND: A single infusion of intravenous zoledronic acid decreases bone turnover and improves bo...
[[abstract]]Objective: The discontinuation of denosumab for the treatment ofosteoporosis can result ...
Introduction: Romosozumab is a monoclonal antibody that binds to sclerostin (an inhibitor of the Win...
Background: Previous bisphosphonate treatment attenuates the bone-forming effect of teriparatide. W...